Pharma channel feed

Phar­ma's bat­tered rep gets a mod­est facelift in the lat­est in­dus­try rat­ings from Gallup — but it's still look­ing pret­ty bad

5 years ago
Bioregnum
Coronavirus

Roche nabs an FDA OK for Gavre­to, trig­ger­ing a heavy­weight bout with ri­vals at Eli Lil­ly

5 years ago
R&D
FDA+

Sam­sung con­struct­ing new $2B 'Su­per Plan­t' rough­ly the size of Amer­i­ca's largest malls

5 years ago
Outsourcing

Amarin los­es patent ap­peal and their brief grip on a car­dio­vas­cu­lar, fish oil em­pire

5 years ago

BIO and a string of CEOs is­sue a call for FDA in­de­pen­dence and against sci­ence-by-press-re­lease

5 years ago
FDA+

Bris­tol My­ers snares an­oth­er ap­proval from the old Cel­gene pipeline, nab­bing an over­looked OK

5 years ago
FDA+

Spurned by the FDA, In­ter­cept brings out the bud­get axe and chops 170 jobs

5 years ago

House Over­sight Com­mit­tee sub­poe­nas Ab­b­Vie over 'woe­ful­ly in­ad­e­quate' doc­u­ment pro­duc­tion in price-goug­ing probe

5 years ago

In the foot­steps of As­traZeneca, No­var­tis com­mits to car­bon-neu­tral sup­ply chain by 2030

5 years ago

Te­va charged — again — for al­leged role in fix­ing gener­ic drug prices, this time by the De­part­ment of Jus­tice

5 years ago

That new biotech com­pound Arie Bellde­grun & Co. have been build­ing in Sea­port? It turns out one fast-grow­ing de­vel­op­er took the whole thing

5 years ago

Sev­en PD-(L)1 play­ers could be vy­ing for a place on Chi­na's drug re­im­burse­ment list. How far will they go?

5 years ago
China

Bris­tol My­ers joins the lab rush in Cam­bridge with plans to con­sol­i­date R&D ops in a biotech cam­pus now un­der con­struc­tion

5 years ago

Opi­oids, price-fix­ing and now kick­backs. Pros­e­cu­tors add an­oth­er ‘en­rich­ing’ scheme to the claims against Te­va

5 years ago

Fed­er­al judge de­nies Mar­tin Shkre­li all but one mo­tion to dis­miss mo­nop­oly claims in the FTC's Dara­prim law­suit

5 years ago
People

Mer­ck pre­pares to fi­nal­ly break ground on $1.3B Lon­don re­search hub

5 years ago
R&D

Mar­tin Shkre­li con­tin­ued to or­ches­trate an­ti-com­pet­i­tive schemes for Dara­prim be­hind bars — FTC

5 years ago
People

The FDA just ap­proved the third Duchenne MD drug. And reg­u­la­tors still don’t know if any of them work

5 years ago
FDA+

Bris­tol My­ers Squibb com­mits $300 mil­lion to com­bat racial dis­par­i­ties, but de­clines to re­lease own de­mo­graph­ic da­ta

5 years ago

Mar­tin Shkre­li's in­fa­mous Dara­prim falls off top 20 most ex­pen­sive drugs list

5 years ago

Ei­sai is cre­at­ing a new US cor­po­rate, R&D HQ in Roche’s old Nut­ley, NJ cam­pus

5 years ago

Covid-19 roundup: Cure­Vac beefs up its uni­corn IPO dreams as bil­lion­aire own­er takes this Covid-19 mR­NA play­er on a forced march to Nas­daq; Ko­dak's $765M deal is put on hold

5 years ago
Outsourcing
Coronavirus

FDA takes the lead on defin­ing es­sen­tial un­der Trump's 'Buy Amer­i­can' ex­ec­u­tive or­der — as phar­ma warns of sup­ply chain dis­rup­tion

5 years ago
Outsourcing
FDA+

Trump reach­es for his pen as long-await­ed ex­ec­u­tive or­der on drug man­u­fac­tur­ing on-shoring fi­nal­ly ar­rives — re­ports

5 years ago
Outsourcing
First page Previous page 251252253254255256257 Next page Last page
A service from the Financial Times